for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
PharmAsia News
   Journal TOC RSS feeds Export to Zotero Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 1875-7774
     Published by Informa plc Homepage  [13 journals]
  • Pharma R&D Center Stage As Japan Preps For New Agency
    • Abstract: Japan’s government is gearing up for major changes in how it funds basic pharma and medtech R&D, with a new agency due to be set up next March as part of a broader health care policy initiative approved earlier this year.
      PubDate: Fri, 17 Oct 2014 02:20:02 -040
  • Emerging Markets Regulatory Tracker: Australia (Vol. 4 No. 65)
    • Abstract: Australia’s TGA eases rules to market for local medical device makers.
      PubDate: Thu, 16 Oct 2014 20:35:01 -040
  • Clinical Trials Approvals Rise In India, But Is It Only In Numbers'
    • Abstract: Data suggests that approvals for clinical trials have accelerated in India over the past year, but the ground reality may be disappointing. CRO executives tell PharmAsia News that sponsors are not keenly participating in India, given restrictive guidelines which are at times impractical to follow.
      PubDate: Thu, 16 Oct 2014 20:25:03 -040
  • India Gives Go-Ahead For Batch Of Biosimilar Trials
    • Abstract: India has permitted more than a dozen clinical trials for rDNA-based drugs this year, including for biosimilar versions of cetuximab (Bristol-Myers Squibb/Eli Lilly’s Erbitux), bevacizumab (Roche Pharma AG's Avastin) and rituximab (Roche/Biogen Idec's Rituxan/MabThera) by a clutch of domestic companies.
      PubDate: Thu, 16 Oct 2014 20:20:02 -040
  • Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
    • Abstract: Third quarter earnings news from Johnson & Johnson was slim on emerging markets insight, but the company’s views on a possible Remicade challenge from Celltrion in the United States came across loud and clear.
      PubDate: Thu, 16 Oct 2014 20:10:03 -040
  • Rare Crackdown Unveils Academic Corruption In China
    • Abstract: As drug makers increasingly look to key researchers and top academic institutions in China for fresh ideas, a recent high-profile academic anti-graft case has shown the perils of the funding system.
      PubDate: Thu, 16 Oct 2014 02:45:00 -040
  • Pharmaceutical Company News from Turkey
    • Abstract: PharmAsia News brings you a look at Turkey’s drug market by capturing recent moves by international and domestic firms.
      PubDate: Thu, 16 Oct 2014 02:05:00 -040
  • Indian Firms Blame U.S. Price Hikes On Compliance Costs
    • Abstract: Put simply, Indian generic firms’ take on why the prices of some of their products have surged in the United States is down to strict inspections and the costs of compliance. Dr Reddy's Laboratories has clarified that it doesn't even market one of the products in question.
      PubDate: Wed, 15 Oct 2014 20:05:01 -040
  • Akynzeo To Help Eisai Over Aloxi Exclusivity Loss'
    • Abstract: The new U.S. regulatory clearance for Eisai and Helsinn Group's Akynzeo is the first to be granted to a single-capsule anti-emetic product targeting two distinct treatment pathways, and will be an important addition to Eisai's oncology franchise.
      PubDate: Wed, 15 Oct 2014 20:00:04 -040
  • Cut Dominance Of Sun, Ranbaxy Combine, Says CUTS
    • Abstract: A united Sun Pharma and Ranbaxy may become a strong global generics firm but its fallout on the Indian market is being studied carefully. Consumer activists have upped their ante raising concerns of impending market dominance in several areas.
      PubDate: Wed, 15 Oct 2014 00:15:03 -040
  • Pharma Import Alert: FDA Working Towards Consistency, Better Decision
    • Abstract: FDA’s broad reorganization may not create the same super-specialization for the import staff that is coming to other parts of the agency, but a process overhaul appears on its way regardless.
      PubDate: Tue, 14 Oct 2014 20:10:02 -040
  • China Health Authority Urges Mega Hospitals To Buy Local High-End Devices
    • Abstract: China’s largest hospitals are now in the front seat to switch to domestic devices, underscored by a recent move by the National Health and Family Planning Commission. Seizing the opportunity, leading domestic makers such as Mindray are ramping up operations with new product lines and enhanced R&D capabilities, notes Citi analyst Richard Yeh.
      PubDate: Tue, 14 Oct 2014 20:05:02 -040
  • GSK Links With Aspen For Non-Core Japan Products
    • Abstract: GSK has entered into a strategic collaboration with Aspen Pharmacare Holdings that will see the big pharma transfer certain mature products to Aspen's new Japanese subsidiary Aspen Japan KK, in return for a 25% stake in the operation.
      PubDate: Tue, 14 Oct 2014 06:00:02 -040
  • Sovaldi: Shooting Star Rather Than Blockbuster'
    • Abstract: Gilead’s hepatitis C virus (HCV) treatment has earned a special place in pharma lore with its rapid rise to about $10 billion in annual sales, bringing with it lots of controversy about the sustainability of specialty drug pricing. Now the product appears poised to make a new reputation: fastest to fall from blockbuster status.
      PubDate: Tue, 14 Oct 2014 00:15:01 -040
  • India Set For New Study On Spurious Drugs
    • Abstract: India continues to move towards improved regulatory oversight in the pharmaceutical segment. It has now initiated steps for a new study on spurious drugs and plans an expansion in the number of adverse drug reactions (ADR) monitoring centers in the country.
      PubDate: Mon, 13 Oct 2014 20:15:01 -040
  • India’s Intas Under Vietnamese Regulatory Lens'
    • Abstract: Intas may be the latest to join dozens of Indian generic companies being investigated for supply of low quality generic drugs.
      PubDate: Mon, 13 Oct 2014 18:45:01 -040
  • The WHO’s Biological Qualifier: Voluntary Or Compulsory'
    • Abstract: The deadline for stakeholders to comment on the World Health Organization's 'biological qualifier' (BQ) proposal has passed, and while submissions to date show a generally warm welcome for the idea, there are disagreements over how extensively it should be applied and whether it should be a voluntary or mandatory scheme.
      PubDate: Sun, 12 Oct 2014 23:10:06 -040
  • Indian Pharma Market Sees Nearly 19% Surge In September
    • Abstract: After a long phase of slow growth, drugmakers in India saw a spike in September as the Southwest Monsoon rains faded, clocking nearly 19%, say analysts.
      PubDate: Sun, 12 Oct 2014 23:10:01 -040
  • Biotron Raising Capital After Promising HCV Results
    • Abstract: The Australian antiviral venture Biotron has announced positive topline clinical results for its first-in-class experimental hepatitis C virus (HCV) drug showing effective cure rates in patients with genotype 3 of the virus who are also co-infected with HIV.
      PubDate: Sun, 12 Oct 2014 23:05:02 -040
  • WuXi Buys U.S.-Based XenoBiotic To Extend Reach To Animal Health
    • Abstract: China-based WuXi PharmaTech completes its purchase of U.S.-based XenoBiotic, gaining it a foothold to serve animal-health related businesses.
      PubDate: Sun, 12 Oct 2014 23:00:03 -040
  • Shionogi Biologic Bolsters MedImmune’s ACS Pipeline
    • Abstract: The out-licensing by Shionogi of an early-stage biologic program to MedImmune fits in with the strategic therapy area interests of the AstraZeneca biologics R&D operation and builds on longstanding ties between the two firms.
      PubDate: Fri, 10 Oct 2014 01:40:04 -040
  • Singapore’s A*Star, Japan’s JST Aim For Device Research
    • Abstract: A pact to increase basic research into novel materials and techniques between Japan and Singapore could see a payoff in medical devices.
      PubDate: Thu, 09 Oct 2014 23:00:01 -040
  • Intas Eyes Biosimilar Lucentis, Avastin To Boost Oncology Presence
    • Abstract: Intas is bracing up for a sizable position in the Indian biosimilars market. Opportunities are large with growing patient numbers and scant supplies of affordable medicines, which are helping steer the company to growth rates upwards of 30%.
      PubDate: Thu, 09 Oct 2014 19:45:03 -040
  • Regulation, Reimbursement Notes From Turkey
    • Abstract: A PharmAsia News update shows Turkey working to get a handle on drug shortages, overuse of antibiotics and the scourge of counterfeit drugs.
      PubDate: Thu, 09 Oct 2014 19:15:01 -040
  • PharmaEngine Drives Asian Trials of Nanobiotix Cancer Therapy
    • Abstract: Taiwan's PharmaEngine Inc. is to add multiple sites in Asia to an international pivotal clinical trial with Nanobiotix SA's nanoparticle cancer therapy hafnium oxide, in a move that should speed up regional development of the radio-enhancing agent.
      PubDate: Thu, 09 Oct 2014 02:45:03 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014